Related Experiment Video
Updated: Jan 2, 2026

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
[New possibilities in antibacterial treatment of intra-abdominal infections caused by multiresistant microflora]
M D Dibirov1, N N Khachatryan1, A I Isaev1
1Department of Surgery and Clinical Angiology at Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia.
Aim:
To determine the place of new drugs with activity against multidrug resistant strains of microorganisms in the treatment of complicated intraabdominal infections.
Material And Methods:
The incidence and distribution of pathogens isolated from intra-abdominal specimens in patients with intra-abdominal infections are analyzed.
Results:
The current situation on the growth of resistant strains among pathogens causing intra-abdominal infections is rewied. New combined drugs for the treatment of multidrug resistant infections - ceftolozane/tazobactam and ceftazidim/avibactam plus metronidazole, has been suggested. Their potential role in empiric and targeted antibacterial treatment of complicated intraabdominal infections is defined.
Conclusion:
Taking into consideration local monitoring data and risk factors of multi resistant strains Ceftolozane/tazobactam in combination with metronidazole can be used in empiric regime of treatment. Due to the high activity on carbapenem resistant strains of Klebsiella pneumonia and the lack of alternatives, it is advisable to use Ceftazidim/avibactam for the targeted therapy.
Insights
New antibiotics like ceftolozane/tazobactam and ceftazidim/avibactam offer options for treating complicated intra-abdominal infections caused by multidrug-resistant organisms.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Complicated intra-abdominal infections (cIAIs) pose treatment challenges due to rising antimicrobial resistance.
- Multidrug-resistant (MDR) pathogens are increasingly implicated in cIAIs.
- Novel antimicrobial agents are needed to combat MDR infections.
Purpose of the Study:
- To evaluate the role of new antibiotics against MDR pathogens in cIAIs.
- To define the potential use of ceftolozane/tazobactam and ceftazidim/avibactam in treating cIAIs.
Main Methods:
- Analysis of pathogen incidence and distribution in intra-abdominal infections.
- Review of current antimicrobial resistance trends.
- Assessment of new drug efficacy against MDR strains.
Main Results:
- Ceftolozane/tazobactam plus metronidazole shows promise for empiric treatment of cIAIs.
- Ceftazidim/avibactam plus metronidazole is effective for targeted therapy against carbapenem-resistant Enterobacteriaceae (CRE), including Klebsiella pneumoniae.
- These agents represent important additions to the therapeutic armamentarium against MDR pathogens in cIAIs.
Conclusions:
- Ceftolozane/tazobactam with metronidazole can be considered for empiric therapy based on local resistance data.
- Ceftazidim/avibactam with metronidazole is recommended for targeted therapy of CRE infections due to its high activity and lack of alternatives.
More Related Videos
09:29In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging
Published on: April 28, 2017
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Related Concept Videos
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Development of Antibiotic Resistance
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Urine Studies II: Urine Culture and Sensitivity Test